Influence of alpha‐adrenoceptor antagonists therapy on stool form in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
| Autor: | Seiji Matsumoto, Sachiko Kasamo, Kazumi Hashizume |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Tamsulosin medicine.medical_specialty Indoles Constipation Urology Prostatic Hyperplasia 030232 urology & nephrology 03 medical and health sciences 0302 clinical medicine Lower Urinary Tract Symptoms Quality of life Lower urinary tract symptoms Surveys and Questionnaires medicine Humans Prospective Studies Defecation Aged 030219 obstetrics & reproductive medicine business.industry Middle Aged Silodosin Hyperplasia medicine.disease Diarrhea Treatment Outcome Neurology Adrenergic alpha-1 Receptor Antagonists Quality of Life International Prostate Symptom Score Symptom Assessment medicine.symptom business medicine.drug |
| Zdroj: | LUTS: Lower Urinary Tract Symptoms. 12:86-91 |
| ISSN: | 1757-5672 1757-5664 |
| DOI: | 10.1111/luts.12289 |
| Popis: | Objectives To evaluate the short-term efficacy and safety of two α1-adrenoceptor (AR) antagonists, tamsulosin and silodosin, in treating patients with untreated lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH), with a focus on stool form. Methods This study was a non-blinded, open-label, prospective randomized comparative study. Tamsulosin or silodosin was administered to patients with untreated LUTS/BPH, and their efficacy and safety in the early stage of treatment were compared using the questionnaire of International Prostate Symptom Score (IPSS)/quality of life (QOL), the Gastrointestinal Symptom Rating Scale (GSRS), and the Bristol Stool Form Scale (BSFS). Results The per protocol set consisted of 22 patients in tamsulosin group (mean age, 70.15 ± 5.70 years) and 20 patients in silodosin group (73.00 ± 6.48 years). The total IPSS and QOL score improved within 2 weeks in both groups. Although the overall GSRS score showed no significant change in either group, "hard stools" score was significantly decreased in silodosin first at week 2, then in both groups at week 4. Furthermore, the subscale score for "constipation" was significantly decreased only in silodosin at week 4. BSFS was significantly increased at week 4 in silodosin alone. Conclusions This study suggests that silodosin was associated with increased digestive symptoms such as diarrhea and loose stools. Therefore, oral drugs for BPH need to be selected by taking into consideration the possibility of digestive symptoms including both the state and type of stools. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|